Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from AnaptysBio

AnaptysBio Whipsaws On Promising Results In Rheumatoid Arthritis Treatment

AnaptysBio stock whipsawed Wednesday despite promising results for its experimental rheumatoid arthritis treatment.

Investors Business Daily

Key Takeaways From AnaptysBio Analyst Ratings

Key Takeaways From AnaptysBio Analyst Ratings

Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on AnaptysBio (NASDAQ:ANAB) in the last three months.

AnaptysBio Surges After Sanofi Takes A Stake In $100 Million Offering

AnaptysBio Surges After Sanofi Takes A Stake In $100 Million Offering

AnaptysBio stock zoomed higher Wednesday after announcing a $100 million offering that includes participation from pharma giant Sanofi.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022

Benzinga's Top Ratings Upgrades, Downgrades For September 13, 2022

Upgrades See all analyst ratings upgrades.

AnaptysBio's Return On Capital Employed Insights

Benzinga Pro data, AnaptysBio (NASDAQ:ANAB) reported Q1 sales of $970.00 thousand. Earnings fell to a loss of $36.26 million, resulting in a 11.42% decrease from last quarter.

AnaptysBio Posts Topline Data From ANB032 Study In Healthy Volunteers

AnaptysBio Inc (NASDAQ:ANAB) announced topline data from a Phase 1 trial of ANB032, an anti-BTLA agonist antibody. Topline data demonstrated favorable safety, tolerability, and rapid and sustained pharmacokinetics and pharmacodynamic profile, supporting the advancement of ANB032 into subsequent patient trials. ANB032 was generally well-tolerated, and no dose-limiting toxicities were observed. The Company said…

inkl

Read news from The Economist, FT, and more,
with one subscription

AnaptysBio To Discontinue Imsidolimab Development In Moderate-to-Severe Acne

AnaptysBio To Discontinue Imsidolimab Development In Moderate-to-Severe Acne

AnaptysBio Inc's (NASDAQ: ANAB) Phase 2 ACORN trial of imsidolimab for moderate-to-severe acne

AnaptysBio's Return On Capital Employed Insights

AnaptysBio's Return On Capital Employed Insights

AnaptysBio (NASDAQ:ANAB) brought in sales totaling $1.01 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 388.12%, resulting in a loss of $32.54 million.

Recap: AnaptysBio Q4 Earnings

Recap: AnaptysBio Q4 Earnings

AnaptysBio (NASDAQ:ANAB) reported its Q4 earnings results on Monday, March 7, 2022 at 09:00 AM. Here's what investors need to know about the announcement. Earnings AnaptysBio reported an EPS of $-1.18.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Western Digital

Micron Technology

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Rheumatoid Arthritis

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play